Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06320379
Other study ID # RB071522
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 15, 2023
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source National University of Natural Medicine
Contact Ryan Bradley, ND, MPH
Phone 503-502-1862
Email rbradley@nunm.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the effects of a readily available dietary supplement on quality of life and digestion in adults with functional dyspepsia.


Recruitment information / eligibility

Status Recruiting
Enrollment 64
Est. completion date December 31, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - ? Adults 18-70 years of age (inclusive) - A self-reported history of symptoms consistent with Functional Dyspepsia (per Rome IV criteria - See Telephone Screening), and self-reported absence of organic disease and infection (e.g., Helicobacter pylori) with or without a formal diagnosis by a healthcare professional. - Adults = 60 years of age must have had a normal upper gastrointestinal endoscopy - Willing to be randomized to take a daily dietary supplement or placebo over the 4-week study period - Not taken antibiotics or other drugs prescribed specifically for symptoms consistent with Functional Dyspepsia (per Rome IV criteria) for a period up to 1 month before the beginning of the study. - On a stable dose of all medications prior to study entry (i.e., consistent dose for a minimum of three months) - On a stable dose of dietary supplements for at least one month prior to enrollment - Willing to avoid initiation of new supplements and/or medications unless otherwise indicated by a healthcare professional - Able to communicate via email, complete computer-administered questionnaires, and to read and write in English. - Approved to be eligible for study participation at the discretion of the Principal Investigators, after review of the Formal Eligibility Screen results. - Non-smokers (including tobacco and cannabis products, combusted or vaporized) - Willing to provide written informed consent and to follow the required protocol Exclusion Criteria: - ? A self-reported history of peptic and/or duodenal ulcers, H. pylori infection, gastroesophageal reflux disease (GERD) explained by upper endoscopy, irritable bowel syndrome (IBS), and other chronic GI disorders. - Positive fecal occult blood test (FOBT) at the clinical screening visit - Current use of digestive enzyme and/or betaine HCL-containing dietary supplements - Current use of prescribed proton-pump inhibitors - Current use of drugs that interfere with gastrointestinal motility, including prokinetic agents. - History of previous abdominal surgery, including gastric surgery, excluding appendectomy. - Individuals with chronic kidney or liver disease, cancer, colorectal disease and/or other rare disorders that at the discretion of the PI or Clinical Investigator may impact their safety or confound trial results - Current involvement or within 14 days prior to screening of a significant diet or weight loss program (such as NutriSystem, Jenny Craig, Atkin's or other low-carb diet programs) or very low-calorie liquid diet programs (such as Optifast, Medifast, and/or HMR) - Hospitalization (for any reason other than a scheduled medical procedure unrelated to Functional Dyspepsia) within 3 months prior to screening - Malignancy within the last 5 years (with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix) - Intake of = 2 standardized alcohol-containing beverages per day, 14 per week, or =4 in any single day within the past 14 days. - Individuals who do not consume, or are allergic to, animal products - Smoking tobacco or nicotine products (combusted or vaporized) - Use of illicit drugs/substances (such as but not limited to cocaine, phencyclidine (PCP), and methamphetamine) within 14 days of screening - Currently participating in another interventional research study, or participated in another interventional research study within 14 days of screening

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Zypan
The study product is a dietary supplement manufactured by Standard Process Inc (i.e., Zypan®). One serving (i.e., two tablets) contains a proprietary blend (595 mg) of the following: Betaine hydrochloride, bovine pancreas Cytosolâ„¢ extract, pepsin (1:10,000), pancreatin (3x), stearic acid (vegetable source), ammonium chloride, bovine spleen, and ovine spleen. Non active ingredients will include cellulose and calcium stearate. Participants will be instructed to take two tablets three times daily with meals
Placebo Comparator
The control supplement will not contain any of the active ingredients in Zypan® and will also be manufactured by Standard Process Inc. Two tablets will contain 435 mg of cellulose (42%), 288 mg rice bran powder (28%), 201 mg of calcium lactate powder (19.5%*), 103 mg citric acid (10%), and 2.6 mg calcium stearate (0.25%)

Locations

Country Name City State
United States Helfgott Research Institute Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
National University of Natural Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Microbiota Relative Abundance and Composition Objective measure of amount and types of gut microbes Baseline
Other Microbiota Relative Abundance and Composition Objective measure of microbiota abundance, composition, diversity Week 4
Other Blood glucose Blood concentrations of glucose Baseline
Other Blood glucose Blood concentrations of glucose Week 4
Other Urea Nitrogen Blood concentrations of Urea Nitrogen Baseline
Other Urea Nitrogen Blood concentrations of Urea Nitrogen Week 4
Other Creatinine Blood concentrations of creatinine Baseline
Other Creatinine Blood concentrations of creatinine Week 4
Other Urea Nitrogen to creatinine ratio ratio of blood concentrations of urea nitrogen to creatinine baseline
Other Urea Nitrogen to creatinine ratio ratio of blood concentrations of urea nitrogen to creatinine Week 4
Other Sodium blood concentrations of Sodium Baseline
Other Sodium blood concentrations of Sodium Week 4
Other Potassium blood concentrations of Potassium Baseline
Other Potassium blood concentrations of Potassium Week 4
Other Chloride blood concentrations of Chloride Baseline
Other Chloride blood concentrations of Chloride Week 4
Other Carbon Dioxide blood concentration of carbon dioxide baseline
Other Carbon Dioxide blood concentration of carbon dioxide week 4
Other Calcium blood concentration of calcium Baseline
Other Calcium blood concentration of calcium Week 4
Other Total Protein Total protein in blood Baseline
Other Total Protein Total protein in blood Week 4
Other Albumin Concentration of albumin in blood Baseline
Other Albumin Concentration of albumin in blood Week 4
Other Globulin Concentration of globulin in blood baseline
Other Globulin Concentration of globulin in blood Week 4
Other Albumin to Globulin ratio Ratio of the blood concentrations of albumin to globulin Baseline
Other Albumin to Globulin ratio Ratio of the blood concentrations of albumin to globulin Week 4
Other Bilirubin Concentrations of bilirubin in blood baseline
Other Bilirubin Concentrations of bilirubin in blood Week 4
Other Alkaline Phosphatase Concentrations of alkaline phosphatase in blood baseline
Other Alkaline Phosphatase Concentrations of alkaline phosphatase in blood Week 4
Other aspartate aminotransferase Concentrations of aspartate aminotransferase in blood Baseline
Other aspartate aminotransferase Concentrations of aspartate aminotransferase in blood Week 4
Other Alanine aminotransferase Concentrations of Alanine aminotransferase in blood baseline
Other Alanine aminotransferase Concentrations of Alanine aminotransferase in blood Week 4
Other Estimated glomerular filtration rate glomerular filtration rate per 1.73 sqM estimated baseline
Other Estimated glomerular filtration rate glomerular filtration rate per 1.73 sqM estimated Week 4
Other White blood cell count Amount of leukocytes in blood baseline
Other White blood cell count Amount of leukocytes in blood Week 4
Other Red blood cell count Amount of erythrocytes in blood baseline
Other Red blood cell count Amount of erythrocytes in blood Week 4
Other Hemoglobin Amount of hemoglobin in blood baseline
Other Hemoglobin Amount of hemoglobin in blood Week 4
Other Hematocrit Amount of hematocrit in blood baseline
Other Hematocrit Amount of hematocrit in blood Week 4
Other Mean corpuscular volume Mean corpuscular volume of erythrocytes baseline
Other Mean corpuscular volume Mean corpuscular volume of erythrocytes Week 4
Other Mean corpuscular hemoglobin Mean corpuscular hemoglobin of erythrocytes baseline
Other Mean corpuscular hemoglobin Mean corpuscular hemoglobin of erythrocytes Week 4
Other Mean corpuscular hemoglobin concentration Mean corpuscular hemoglobin concentration of erythrocytes baseline
Other Mean corpuscular hemoglobin concentration Mean corpuscular hemoglobin concentration of erythrocytes Week 4
Other Erythrocyte distribution width Erythrocyte distribution width baseline
Other Erythrocyte distribution width Erythrocyte distribution width Week 4
Other Platelet count amount of platelets in blood baseline
Other Platelet count amount of platelets in blood Week 4
Other Neutrophils amount of neutrophils in blood baseline
Other Neutrophils amount of neutrophils in blood Week 4
Other Band Neutrophils Neutrophils band form per 100 leukocytes baseline
Other Band Neutrophils Neutrophils band form per 100 leukocytes Week 4
Other Absolute band neutrophils Amount of Neutrophils band form baseline
Other Absolute band neutrophils Amount of Neutrophils band form Week 4
Other Metamyelocytes Amount of metamyelocytes per 100 leukocytes baseline
Other Metamyelocytes Amount of metamyelocytes per 100 leukocytes Week 4
Other Absolute Metamyelocytes Amount of metamyelocytes baseline
Other Absolute Metamyelocytes Amount of metamyelocytes Week 4
Other Myelocytes Amount of metamyelocytes per 100 leukocytes baseline
Other Myelocytes Amount of metamyelocytes per 100 leukocytes Week 4
Other Absolute Myelocytes Amount of myelocytes baseline
Other Absolute Myelocytes Amount of myelocytes Week 4
Other Promyelocytes Amount of promyelocytes per 100 leukocytes baseline
Other Promyelocytes Amount of promyelocytes per 100 leukocytes Week 4
Other Absolute Promyelocytes Amount of promyelocytes baseline
Other Absolute Promyelocytes Amount of promyelocytes Week 4
Other Absolute Neutrophils Amount of neutrophils in blood baseline
Other Absolute Neutrophils Amount of neutrophils in blood Week 4
Other Lymphocytes Amount of lymphocytes in blood per 100 leukocytes baseline
Other Lymphocytes Amount of lymphocytes in blood per 100 leukocytes Week 4
Other Reactive Lymphocytes Amount of reactive lymphocytes in blood per 100 leukocytes baseline
Other Reactive Lymphocytes Amount of reactive lymphocytes in blood per 100 leukocytes Week 4
Other Absolute Lymphocytes Amount of reactive lymphocytes in blood baseline
Other Absolute Lymphocytes Amount of reactive lymphocytes in blood Week 4
Other Monocytes Amount of monocytes in blood per 100 leukocytes baseline
Other Monocytes Amount of monocytes in blood per 100 leukocytes Week 4
Other Absolute monocytes Amount of monocytes in blood baseline
Other Absolute monocytes Amount of monocytes in blood Week 4
Other Eosinophils Amount of eosinophils in blood per 100 leukocytes baseline
Other Eosinophils Amount of eosinophils in blood per 100 leukocytes Week 4
Other Absolute Eosinophils Amount of eosinophils in blood baseline
Other Absolute Eosinophils Amount of eosinophils in blood Week 4
Other Basophils Amount of basophils in blood per 100 leukocytes baseline
Other Basophils Amount of basophils in blood per 100 leukocytes Week 4
Other Absolute Basophils Amount of basophils in blood baseline
Other Absolute Basophils Amount of basophils in blood Week 4
Other Blasts Amount of blasts in blood per 100 leukocytes baseline
Other Blasts Amount of blasts in blood per 100 leukocytes Week 4
Other Absolute Blasts Amount of blasts in blood baseline
Other Absolute Blasts Amount of blasts in blood Week 4
Other Nucleated red blood cells Amount of nucleated erythrocytes per 100 leukocytes baseline
Other Absolute Nucleated red blood cells Amount of nucleated erythrocytes in blood baseline
Other Absolute Nucleated red blood cells Amount of nucleated erythrocytes in blood Week 4
Other Platelet mean volume Mean volume of platelets in blood baseline
Other Platelet mean volume Mean volume of platelets in blood Week 4
Primary Protein Assimilation Concentrations of Amino Acids in Blood Baseline
Primary Protein Assimilation Concentrations of Amino Acids in Blood Week 4
Secondary Mineral concentrations in blood Mineral concentrations in blood as measured by Genova Diagnostics NutrEval Baseline
Secondary Mineral concentrations in blood Mineral concentrations in blood as measured by Genova Diagnostics NutrEval Week 4
Secondary Fat-soluble vitamin concentration in blood Fat-soluble vitamin concentrations in blood as measured by Genova Diagnostics NutrEval Baseline
Secondary Fat-soluble vitamins Fat-soluble vitamin concentrations in blood as measured by Genova Diagnostics NutrEval Week 4
Secondary Leeds Dyspepsia Questionnaire Subjective measure of digestive symptoms Baseline
Secondary Leeds Dyspepsia Questionnaire Subjective measure of digestive symptoms Week 4
Secondary Patient Reported Outcomes Measurement Information System (PROMIS)-29 Physical Function Subscale Subjective measure of Quality of life related to physical function Baseline
Secondary Patient Reported Outcomes Measurement Information System (PROMIS)-29 Physical Function Subscale Subjective measure of Quality of life related to physical function Week 4
See also
  Status Clinical Trial Phase
Recruiting NCT06094062 - Smartphone App-assisted PPI N/A
Completed NCT03941288 - Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia Phase 2
Completed NCT04429802 - The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Withdrawn NCT02863822 - Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia. N/A
Recruiting NCT00978159 - Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Phase 4
Completed NCT00723502 - Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients Phase 2
Completed NCT00217347 - Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy N/A
Completed NCT00148603 - Montelukast in the Treatment of Duodenal Eosinophilia N/A
Terminated NCT00220844 - Tricyclic Antidepressants (TCAs) on Gastric Emptying N/A
Completed NCT00232102 - Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia Phase 3
Completed NCT00110968 - Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia Phase 3
Completed NCT00232037 - Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia Phase 3
Completed NCT00164996 - Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia Phase 3
Recruiting NCT05718960 - Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia N/A
Terminated NCT04247100 - A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders N/A
Completed NCT05750641 - The Efficacy of Removal of Animal Milk From the Diet in Functional Dyspepsia: A Cross-sectional Study
Completed NCT03252743 - ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study. N/A
Completed NCT04697641 - Helicobacter Pylori Eradication in Functional Dyspepsia N/A
Recruiting NCT04918329 - Functional Digestive Disorders Observatory